Early effects of bone marrow-derived mononuclear cells on lung and kidney in experimental sepsis

Carla M Silva1, Debora S Ornellas2, Felipe M Ornellas3

  • 1Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Laboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil; National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil.

Abstract

Insights

Early therapy with bone marrow-derived mononuclear cells (BMDMCs) significantly reduced lung and kidney damage in experimental sepsis. This study highlights BMDMCs as a promising therapeutic agent for sepsis-induced organ injury.

Area of Science:

  • Regenerative Medicine
  • Immunology
  • Sepsis Research

Background:

  • Sepsis is a life-threatening condition characterized by a dysregulated host response to infection.
  • Previous studies explored bone marrow-derived mononuclear cells (BMDMCs) in lung injury models, but early effects on both lung and kidney in polymicrobial sepsis remain unclear.

Purpose of the Study:

  • To investigate the early therapeutic effects of BMDMC administration on lung and kidney damage in a mouse model of experimental polymicrobial sepsis.

Main Methods:

  • Cecal ligation and puncture (CLP) was used to induce sepsis in female C57BL/6 mice.
  • Animals received either saline or 10^6 BMDMCs intravenously 1 hour post-CLP.
  • Lungs and kidneys were analyzed for histological damage and molecular markers at 6, 12, and 24 hours.

Main Results:

  • BMDMCs reduced lung injury scores and keratinocyte chemoattractant (KC) mRNA expression in lungs.
  • Kidney analysis revealed reduced tubular injury, neutrophil gelatinase-associated lipocalin (NGAL), and altered high-mobility-group-box (HMGB)-1 levels post-BMDMC treatment.
  • Interleukin-10 (IL-10) mRNA levels were elevated in BMDMC-treated groups at specific time points.

Conclusions:

  • Early intravenous BMDMC therapy effectively mitigated lung and kidney damage in experimental polymicrobial sepsis.
  • BMDMCs demonstrate potential as a therapeutic strategy for managing sepsis-induced organ dysfunction.